26.6 C
Vientiane
Wednesday, September 10, 2025
spot_img
Home Blog Page 1156

Zylox-Tonbridge Announces 2024 Annual Results: Achieves Full-Year Profit for the First Time with Net Profit Exceeding USD 14 Million

HANGZHOU, China, March 29, 2025 /PRNewswire/ — On March 20, Zylox-Tonbridge Medical Technology Co., Ltd. (Stock Code: 2190.HK, hereinafter referred to as “Zylox-Tonbridge” or the “Company”) released its 2024 annual results. In 2024, the Company reported revenue of USD 109.4 million, a year-on-year increase of 48.3%, and achieved a net profit exceeding USD 14 million, marking its first full-year profitability.

Amid a dynamic market environment, Zylox-Tonbridge benefited from the economies of scale driven by sustained revenue growth, entering a new phase of sustainable profitability. This fully demonstrates the Company’s robust capabilities in developing comprehensive product solutions, delivering high-quality products, and operating efficiently. Looking ahead, Zylox-Tonbridge remains committed to its mission of “Innovation for Quality Life”, focusing on advancements in medical technology to improve high-quality healthcare and drive the Company’s long term growth.

Strong Performance in Centralized Procurement and Continued Overseas Expansion

In 2024, the Company actively seized opportunities in centralized procurement, securing successful multiple bids by leveraging its robust and high-quality product portfolio. These achievements are expected to accelerate product penetration in hospitals and enhance market competitiveness, laying a solid foundation for sustained growth.

In the “3+N” provincial alliance centralized procurement led by Hebei, our SilverSnake Intracranial Support Catheter fully demonstrated its advantages in the A group for its respective category, winning the bid with the highest ranking. During the national-level venous stent procurement, the ZYLOX Penguin Peripheral Venous Stent System became the only domestic bidder to win the first rule of iliac vein indication. In the vascular intervention product procurement led by Hebei Province, our products, including the Kylin Flow Diverter, White Horse Intracranial PTA Balloon Catheter (Rx) and three peripheral balloon products, won bids, each securing a leading position in their respective categories. As centralized procurement policies deepen, the Company has established an extensive distribution network covering over 3,000 hospitals.

In 2024, Zylox-Tonbridge allocated dedicated resources across key functions, including R&D, regulatory affairs, and manufacturing, further expanding its overseas footprint. Currently, 20 of the Company’s products are commercialized in 24 countries and regions, including Germany, Italy, Argentina, Brazil, and the UAE, spanning Europe, South America, and the Middle East. The Company is conducting post-market clinical trials for the Zenflex™ Peripheral Stent System and ZENFLEX™ Pro Peripheral Drug-Eluting Stent System in overseas markets while actively participating in international academic conferences such as WLNC 2024, LINC 2024, and CIRSE 2024 to enhance brand influence abroad. The Company’s overseas revenue reached USD 3.2 million in 2024, with a four-year compound annual growth rate of 87%.

Driven by Innovation: Pioneering Cutting-Edge Medical Technologies

In 2024, Zylox-Tonbridge launched multiple innovative products, offering patients more comprehensive solutions. The Company is also actively exploring “AI + Healthcare” technologies to empower product innovation and service upgrades.

Among its breakthroughs, the launch of ZYLOX Penguin Peripheral Venous Stent System, a product of medical-engineering collaboration, became another milestone in the Company’s efforts to address peripheral venous diseases. The Kylin Flow Diverter, independently developed by Zylox-Tonbridge, is China’s first fully visible distal closed flow diverter stent. Meanwhile, ZYLOX Unicorn Suture-mediated Closure System, the first domestically manufactured vascular suture product, has broken the market monopoly of imported brands in puncture site closure solutions.

The Company’s collaboratively developed ZYLOX Pantheris™ Peripheral OCT-Guided Atherectomy Catheter and ZYLOX Tigereye ST™ OCT-Guided Peripheral Vascular Chronic Total Occlusion-crossing Catheter obtained approval from the NMPA to enter the special review procedure for innovative medical devices (innovation channel), which are expected to launch in 2025. Additionally, Zylox-Tonbridge is focusing on next-generation real-time imaging AI diagnostics and analysis technologies to improve precision in vascular interventions and develop personalized treatment solutions.

As of the announcement date, the Company has established a pipeline of 66 products. Among these, 47 have received NMPA approval, 8 have obtained EU CE marks, and several others have been approved for sale in countries such as Germany and the UK.

Operational Excellence: Entering the Sustainable Profitability Stage

With growing revenue, Zylox-Tonbridge’s operational efficiency continues to rise. In 2024, the Company reduced its R&D, sales, and administrative expense ratios by 20, 9, and 10 percentage points, respectively, compared to 2023, propelling it into a new phrase of sustainable profitability.

At its Hangzhou and Zhuhai manufacturing bases, the Company has invested in automated and digital production lines, optimized lean processes, and strengthened supply chain management to increase the localization rate of core materials, ensuring both product quality and production efficiency. Since fully launching commercialization in late 2020, over 800,000 of the Company’s products have been used clinically, earning recognition and trust from medical professionals.

Moving forward, Zylox-Tonbridge will uphold its commitment to “Innovation for Quality Life,” increasing investments in medical technology to provide global patients with high-quality, affordable medical devices and solutions. The Company aims to ensure that everyone can benefit from advanced medical technologies, contributing to the progress of the healthcare industry.

CASEKOO Watering Spring: Spin into Spring Vibes with the MagicStand Pro

LOS ANGELES, March 29, 2025 /PRNewswire/ — CASEKOO is proud to introduce its highly anticipated Spring Collection, a series of phone cases designed to inspire environmental consciousness. At the heart of the collection lies the thoughtfully designed “Watering Spring” case, each comes with a unique seed card, inviting users to plant, nurture, and witness the growth of their own flowers or plants. Still part of the Magic Stand Pro series, CASEKOO seamlessly incorporates the built in stand into every design. The latest Pro version offers full 360° rotation, delivering unmatched flexibility to support your phone at any angle.


At its core, the design symbolizes rejuvenation, where a verdant green watering can transforms into a vessel of life, nurturing the earth with its boundless abundance. From its gracefully curved spout flows not mere water, but the spirit of spring itself—birds soaring with wings outstretched, mammals leaping in unrestrained joy, and flowers bursting into bloom in a symphony of colors. The birds, adorned in soft pastels and vibrant hues, symbolize freedom and the return of warmth. The mammals, intricately detailed, exude playfulness and vitality, their movements frozen in mid-leap as if captured in a moment of pure exuberance. The flowers, with their delicate petals and lush greenery, embody growth and the timeless beauty of life’s cyclical dance. Together, they form a harmonious tableau that feels alive, as though the scene is in perpetual motion, pouring forth the boundless energy of spring.

Yet, CASEKOO invites you to look beyond the surface and discover the deeper meaning woven into this design. The watering can, from another perspective, stands as a timeless emblem of nature’s infinite possibilities. Its elegantly curved spout pours forth not just a drop of spring, but a cascade of liquid hope. This flowing stream carries with it the promise of new beginnings—the first breath of a sprouting seed, the tender unfurling of a dream, and the radiant spark of hope that ignites the soul.

With the “Watering Spring” case, CASEKOO has created a symbol of hope and a testament to the power of incremental change. Just as a single seed card cannot stop global warming on its own, every additional plant nurtured helps reduce the harm caused to our planet, bit by bit. Similarly, CASEKOO strives to improve its products every day, refining them with precision and care. Each small enhancement is a step forward, allowing our followers to witness progress and see hope in action. This collection is not just a product—it’s a story of perseverance, a dream of a greener future, and a promise to keep moving forward, one step at a time.

 

Embassy Group Launches India’s Only Integrated GCC Platform – ‘EMBARK’

A Complete Solution for Establishing and Scaling Global Capability Centers in India

BENGALURU, India, March 29, 2025 /PRNewswire/ — Embassy Group, one of India’s leading real estate and business ecosystem developers, today announced the launch of Embark, the country’s first fully integrated platform designed to enable and accelerate the establishment of Global Capability Centers (GCCs). As a one-stop execution partner, Embark will provide a seamless, end-to-end solution to help global enterprises Design, Execute and Evolve their India GCCs with ease.

India has established itself as the GCC Capital of the World, with over 1,700 GCCs and 400+ new entrants in the last five years. This dynamic landscape is driving high-impact strategic work and serving as a global integrated extension of corporate headquarters with more than 6,500 global roles based in India. Coupled with this, India offers the perfect foundation for GCCs to flourish—boasting the world’s largest STEM talent pool, thriving tech and R&D ecosystem, cost advantages, and robust macroeconomic environment.

However, setting up and integrating a world-class hub can be a complex process, requiring deep expertise across talent acquisition, organisational design and culture, real estate, compliance and operational excellence — a gap that Embark aims to bridge with a strategic, hands-on approach led by a team of practitioners. 

Jitu Virwani, Chairman & Managing Director, Embassy Group, said,

“With Embark, our goal is simple – to transform the GCC set up experience in India, by providing companies with a seamless, strategic as well as execution-focused platform that removes complexity and accelerates success. This new vertical is a natural extension of Embassy Group’s legacy – we have been building and managing world-class workspaces for leading global companies for over 30 years. Now, with Embark, we go beyond infrastructure to deliver a fully integrated GCC platform, which will make the entry as well as evolution for global enterprises an effortless experience. This new venture is backed by a seasoned leadership team with end-to-end expertise to deliver tailor-made, high-impact GCC solutions.”

EMBARK: A complete solution – from Concept to Impact, seamlessly executed

As the only integrated platform of its kind, Embark provides a turnkey solution for establishing GCCs, offering:

  • Strategy & Design – Vision alignment, Location strategy, Organizational design
  • India Entry & Operations – Compliance (set-up, HR, legal, finance), Infrastructure (office space, facility & IT services), Accelerated hiring, Cultural integration as well as Workforce management
  • Evolution for long-term success – Transformation advisory, Future-ready workforce, and Operational excellence

Embassy Group has been a pioneer in Indian real estate, and real estate is an integral part of Embark’s offering. Furthermore, Embark will leverage WeWork India Management Limited’s (“WeWork India”)’ expertise to deliver high quality managed office solutions.

With over three-decade-long experience in creating and managing premium business environments for Fortune 500 companies, global tech firms, and innovation-driven enterprises, Embassy Group provides the full ecosystem that global executives and teams need to thrive in India. Its diversified portfolio spans 54+ million square feet of commercial real estate, 45 million square feet of residential developments, co-working and managed office solutions, premium hospitality & co-living spaces, end-to-end facility management, and education —cementing its reputation as a real estate powerhouse.

By leveraging its local expertise, industry partnerships, and deep insights, Embark aims to redefine the way global businesses enter and scale in India—creating a seamless, efficient, and highly successful GCC expansion journey.

For more information, visit www.embarkgcc.com

Media Contact:
Sera Rishad Minocher | sera.r@embassyindia.com

About Embassy Group

Embassy Group is a leading real estate developer. The over 75 million sq. ft. of commercial, residential, industrial and warehousing, hospitality, services, retail, and education spaces we have delivered and manage emphasise high standards of quality, world-class services, environmental management, and safety. Founded in 1993, our operations now span the Indian and international markets of Bengaluru, Chennai, Thiruvananthapuram, Mumbai, Pune, the NCR, Serbia, and more. Our 21 million sq. ft. of ready residential developments encompass branded residences, uber-luxury villas, exclusive villaments, sky condominiums, integrated developments, senior living, and contemporary homes. Embassy was a sponsor of India’s first publicly listed and Asia Pacific’s largest Real Estate Investment Trust (REIT). Further information is available at www.embassygroup.com

 

Agentic AI and Scalable Enterprise Integration Catalyse AI Industry Growth

Top 10 AI growth opportunities to drive innovation, efficiency, and responsible AI development

LONDON, March 29, 2025 /PRNewswire/ — Artificial Intelligence (AI) is set to revolutionise industries in 2025, with emerging technologies such as Agentic AI, MLOps platforms, and foundational models driving unprecedented advancements in automation, efficiency, and ethical AI governance. As businesses accelerate their digital transformation, AI is becoming a cornerstone of enterprise applications, reshaping customer experience (CX), operational efficiency, and IT infrastructure.

Frost & Sullivan has unveiled its top 10 AI growth opportunities for 2025 in a recent report, highlighting the increasing democratisation of AI access, enterprise readiness for AI adoption, and the growing demand for low-code development platforms, AI-driven automation, and digital infrastructure investments.

Enterprise AI Adoption and Growth Opportunities in 2025

As AI capabilities rapidly evolve, businesses are increasingly investing in AI to drive value creation and strategic differentiation. However, organisational challenges, data readiness issues, and the need for seamless integration with existing infrastructure continue to hinder large-scale adoption.

A recent Frost & Sullivan survey found that 46% of enterprises require third-party system integration support for AI adoption, presenting a major growth opportunity for IT services providers specialising in AI implementation, cloud integration, and AI-driven analytics.

According to Nishchal Khorana, Associate Partner at Frost & Sullivan, AI service providers are aggressively expanding capabilities to capitalise on emerging opportunities, focussing on talent upskilling, digital asset development, and strategic partnerships to enhance market differentiation. “As organisations seek guidance in AI adoption, IT service providers can move up the value chain by offering domain expertise, technology consulting, and advisory services,” he explains.

“To compete in transformational AI projects, providers must build comprehensive service portfolios, ensuring end-to-end delivery across diverse applications and infrastructure. Emphasising trust, safety, and reliability frameworks will be critical for securing large-scale enterprise adoption,” Khorana adds.

Agentic AI: The Next Frontier of Autonomous Intelligence

Agentic AI is emerging as a disruptive force in artificial intelligence, enabling greater autonomy and decision-making capabilities with minimal human intervention. Building on Generative AI (GenAI) and robotic process automation (RPA), it enhances efficiency in tackling complex business challenges.

As adoption accelerates, Agentic AI presents significant growth opportunities for AI-driven applications, platforms, and services, reshaping enterprise operations and human-AI interaction.

During the remainder of the year, we will witness AI become more deeply embedded into enterprise applications, with organisations adopting best practices for responsible AI development. Companies that prioritise infrastructure, data, talent and security will be best positioned to scale AI implementations and lead in the AI-driven economy, Khorana concludes.

Click here to unlock growth potential and explore the future of AI in enterprise innovation.

YOUR TRANSFORMATIONAL GROWTH JOURNEY STARTS HERE. Frost & Sullivan’s Growth Pipeline Engine, transformational strategies and best-practice models drive the generation, evaluation, and implementation of powerful growth opportunities. Is your company prepared to survive and thrive through the coming transformation? Join the Journey

Editor’s Note

To arrange an interview or for any questions, please contact:

Contact:

Kristina Menzefricke
Marketing & Communications
Global Customer Experience, Frost & Sullivan
kristina.menzefricke@frost.com

Baidu’s Apollo Go Partners with Autogo in Plan to Build Abu Dhabi’s Largest Robotaxi Fleet

  • During the initial period, Apollo Go and Autogo will collaborate to deploy dozens of autonomous vehicles in Abu Dhabi, with phased expansion planned ahead of full commercial operations by 2026.
  • This marks Apollo Go’s further expansion into the UAE, applying its proven autonomous driving technology and operational experience from China.
  • Apollo Go and Autogo will collaborate to scale commercial operations and expect to build Abu Dhabi’s largest driverless fleet.

BEIJING, March 29, 2025 /PRNewswire/ — Baidu (NASDAQ: BIDU and HKEX: 9888) announced today (March 29, 2025, Beijing Time) that its autonomous ride-hailing service, Apollo Go, has entered into a strategic partnership with Autogo, a UAE-based autonomous mobility company and subsidiary brand of Kintsugi Holding, with the goal of deploying the largest fully driverless fleet in Abu Dhabi. Through this strategic partnership, Apollo Go and Autogo aim to bring next-generation mobility to the streets of the UAE capital.

Initial trials of dozens of Apollo Go autonomous vehicles will be deployed in select areas of Abu Dhabi, with phased expansion planned ahead of full commercial operations by 2026. The trials in Abu Dhabi will be conducted in close coordination with the city’s Integrated Transport Centre (ITC), ensuring that the service aligns with local transport strategies, regulatory standards, and infrastructure planning as part of the emirate’s smart mobility goals.

By combining Apollo Go’s cutting-edge technology in autonomous driving and extensive experience in large-scale fleet operations, this partnership will enable Abu Dhabi and Autogo to rapidly build a smart mobility service ecosystem. Apollo Go’s proven solutions will integrate seamlessly with Autogo’s local expertise and market insight, offering residents a more convenient and sustainable transportation experience.

As Baidu’s robotaxi arm, Apollo Go stands as China’s largest of its kind. Since February 2025, Apollo Go has commenced 100% fully driverless operations across over 10 cities in China and continues to expand. In November 2024, Apollo Go was granted the first autonomous vehicle pilot license in Hong Kong, its first entry into a right-hand drive, left-hand traffic market.

Backed by 150 million kilometers of safe autonomous driving track record and over 10 million cumulative rides, Apollo Go brings proven technology and operational experience to the UAE, and is poised to enhance the city’s transportation efficiency and smart mobility solutions. As an all-electric, on-demand service, Apollo Go also promotes a more sustainable approach to urban transportation — helping reduce emissions, ease congestion, and reshape the city landscape.

Looking ahead, Apollo Go and Autogo will work together to scale commercial operations of robotaxi services to serve more users and contribute to Abu Dhabi’s smart city vision.

About Baidu

Founded in 2000, Baidu’s mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on the NASDAQ under “BIDU” and HKEX under “9888.” One Baidu ADS represents eight Class A ordinary shares.

Media Contact:
Intlcomm@baidu.com

LifeTech Scientific Corporation Announced 2024 Annual Results: Revenue Exceeded RMB1.3 billion, and International Business Increased by 26%

SHENZHEN, China, March 29, 2025 /PRNewswire/ — LifeTech Scientific Corporation (the “Company” or “LifeTech”, Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiaries (the “Group”) announced the audited consolidated results for the year ended 31 December 2024 (the “Reporting Period”).

  • Revenue increased steadily: The revenue of the Group was approximately RMB1,303.7 million for the year ended 31 December 2024, representing a year-on-year growth of approximately 2.9%.
  • International business made a significant growth: The overseas sales of the Group was approximately RMB346.6 million for the year ended 31 December 2024, representing a year-on-year growth of approximately 26.0%. The two largest overseas markets, namely Asia (excluding China’s mainland) and Europe, achieved a sustained rapid growth during the Reporting Period, increasing by approximately 33.6% and 18.6% as compared with the same period of 2023, respectively.
  • Profitability:During the Reporting Period, gross profit was approximately RMB981.4 million, while the gross profit margin was approximately 75.3%. Net profit for the year ended 31 December 2024 was approximately RMB168.5 million, and net profit attributable to owners of the Company for the year ended 31 December 2024, was approximately RMB222.4 million.

International Business Achieved Significant Growth, Domestic Market Solidified Foundation for Development

The Company steadfastly pursued its mission to meet unmet clinical treatment needs worldwide through a strategic lens focused on innovation and global outreach. During the Reporting Period, the Group has showcased its commitment by rolling out a rich product portfolio of cutting-edge technology and premium academic services, alongside the synergistic amalgamation of its expertise in branding, patents, distribution networks, clinical trials, market registration, and management of global operations. With the effective implementation of the internationalization development strategies, the Group’s international business has maintained sustained rapid growth. The revenue generated from overseas market of the Group was approximately RMB346.6 million, representing a significant year-on-year growth of approximately 26.0%, accounted for about 26.6% of the total revenue of the Group. Meanwhile, Asia (excluding China’s mainland) and Europe were the two largest overseas market of the Group, continued to maintain a strong growth rate during the Reporting Period, increasing by approximately 33.6% and 18.6% as compared with the same period of 2023, respectively. The sales generated from the Asia market and European market accounted for approximately 11.7% and 10.1% of the total revenue of the Group, respectively.

China’s mainland remained the foundation and the largest market of the Group. During the Reporting Period, the domestic sales of the Group was approximately RMB957.1 million, which accounted for approximately 73.4% of the total revenue of the Group. The Group’s key products, including congenital heart disease (CHD) occluders, left atrial appendage (LAA) occluders, aortic stent grafts and vena cava filters, continued to develop in depth in the China’s mainland market during the reporting period, with a wide coverage and a solid market foundation, and continuously maintained its leading position in China market.

Core Business Demonstrated Development Resilience

 Structure Heart Diseases (SHD) Business

The products offered by the Group in the SHD business mainly include CHD occluders and LAA occluders.  The turnover contributed by the SHD business for the year ended 31 December 2024 was approximately RMB527.6 million, representing a year-on-year growth of approximately 6.4%.

The LAA occluder of the Group firmly ranks first in terms of market share among domestic peers in the global market. The revenue generated from the sales of LAA occluders increased by approximately 12.4% as compared with the corresponding period of 2023. Meanwhile, the Group is currently selling three generations of CHD occluders in the global market, aiming to meet various market needs through a differentiated product strategy. During the Reporting Period, the revenue generated from the sales of CHD occluders increased by approximately 2.9% as compared with the same period of 2023.

The Group has a diversified product portfolio in the treatment of SHD. Continuous technological innovation and product upgrading will further refine and enrich the product portfolio and sales layout of the Group’s SHD business in the global market.

Peripheral Vascular Diseases (PVD) Business

Products offered by the Group in the PVD business mainly included vena cava filters, thoracic aortic aneurysm stent grafts, abdominal aortic aneurysm stent grafts and iliac artery bifurcation stent grafts. During the Reporting Period, the turnover contributed by the PVD business was approximately RMB751.1 million, representing a year-on-year growth of approximately 6.2%.

Among these products, the market shares of vena cava filters and stent grafts occupy a leading position in the domestic market. The revenue generated from the sales of stent grafts and vena cava filters increased by approximately 8.3% and decreased by approximately 3.4% as compared with the same period of 2023, respectively.

The Group is striving to provide global patients with technology-leading systemic and comprehensive interventional medical devices solutions to treat PVD. Currently, the Group has taken the lead in building an overall solution for endovascular interventional treatment of the aorta in the global industry. This could bring the Group’s PVD business with a strong and long-term competitive edge in the global market.

Cardiac Pacing and Electrophysiology (CPE) Business

The Group is the first domestic manufacturer in China with a complete product portfolio of domestic implantable cardiac pacemakers with international-level technology and functions. During the Reporting Period, the turnover contributed by the CPE business was approximately RMB25.0 million.

Innovation at the Core to Drive the Sustainable Growth

 Independently developed innovative medical device products could maintain the long-term competitive strengths of the Group to support its solid and sustained development. With a robust lineup of pipeline products, the Group is at the forefront of innovation, boasting products with substantial growth potential and broad market appeal. During the Reporting Period, research and development expenses of the Group were approximately RMB302.9 million (excluding capitalized expenditure) to continuously strengthen its innovation capabilities and accelerate the development and commercialization of its novel products. 

Smooth progress of product commercialization:

  • Futhrough™Endovascular Needle System, Thrombectomy Aspiration Pump, Balloon Guided Catheter, Distal Access Catheter Kits, Intracranial Aspiration Catheter and HeartTone™ Implantable Cardiac Pacemaker compatible with magnetic resonance imaging (“MRI”) obtained the National Medical Products Administration (“NMPA”) certification;
  • HeartR™ PDA Occluder, Cera™ PDA Occluder, CeraFlex™ PDA Closure System and Fustar™ Steerable Introducer obtained the CE MDR (Medical Device Regulation) certification. Such products have previously obtained the CE MDD (Medical Device Directive) certification;
  • Aortic Stent Graft System (consists of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System) 【1, Aortic Arch Stent Graft System (consists of the Ankura™ Plus Aortic Arch Stent Graft System and CSkirt™ Aortic Arch Branch Stent Graft System), Thoracoabdominal Artery Stent Graft System (consists of the G-Branch™ Thoracoabdominal Aortic Stent Graft System, SilverFlow™ PV Peripheral Vascular Stent Graft System and Aortic Extension Stent Graft System), Peripheral Balloon Dilatation Catheter (Large diameter) 【2, Iliac Bifurcation Device (consists of the G-iliac™ Pro Iliac Bifurcation Stent Graft System and SilverFlow™ Pro Internal Iliac Stent Graft System), Closure Delivery System, SteerEase™-m Introducer, Yoscop™ Multi-loop Snare System and Microcatheter are pending registration approval in China;

Note 【1】【2:Market registration of these two products was approved by NMPA in 2025.

  • Aortic Stent Graft System (consists of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System), Fitaya™ Vena Cava Filter System, Futhrough™ Stent Graft Balloon Catheter, Yuranos™ Abdominal Aortic Stent Graft System, and G-iliac™ Iliac Bifurcation Device are pending registration approval of CE certification;
  • Cera™ PFO Occluder, CS™ Concave Supra-arch Branched Stent-Graft System and X-Clip™ Mitral Valve Clip System are currently at the stage of the pre-registration clinical enrollment in China;
  • IBS Titan™ Sirolimus-Eluting Iron Bioresorbable Peripheral Scaffold System is currently at the stage of clinical enrollment in China and in Europe and its CE registration application has been submitted; and
  • IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System has successfully completed the oneyear follow-up and two-year imaging follow-up of the phase II clinical study, and also successfully completed the one-year follow-up of the phase III clinical study, further confirming its safety and efficacy. Additionally, its CE registration application has been submitted.

Intellectual Property Rights:

Intellectual property is an internal driving force to improve the Group’s core competitiveness in the medical device market. As at 31 December 2024, the Group had filed a total of 2,426 valid patent applications, of which 1,089 patents were registered and valid.

The Chairman and CEO of LifeTech, Mr. XIE Yuehui Said:
In 2024, the Group continued to forge ahead in a complex and volatile market environment. We faced challenges head-on and made joint efforts in research and development, network expansion, production and quality control, and internal control management. We continuously consolidated our leading position in the domestic market and achieved sustained and rapid growth in the international market, demonstrating strong resilience in business development and growth potential.

The global medical device industry will embrace tremendous development opportunities driven by both technological innovation and demand upgrading. We will continue to be empowered by innovation, earn a reputation through quality, solidify the foundation for development, and keep delving deeper and making breakthroughs in the global market. We will bring sustainable differential competitive advantages through technological innovation so as to occupy a higher share of the global market and enable more patients to benefit from our innovative products and advanced therapies.

Meanwhile, we will also strategically explore new growth opportunities around the globe, integrate and efficiently utilize internal and external advantageous resources, and constantly enhance the overall value of the Group and its global industry influence, so as to create greater value for shareholders and all relevant parties.

About LifeTech Scientific Corporation:

Established in Shenzhen, China in 1999, LifeTech Scientific Corporation (Stock Code: 1302.HK) is dedicated to the research and development, manufacturing, and marketing of minimally invasive interventional medical devices for the treatment of cardio-cerebrovascular and peripheral vascular diseases. The Company offers innovative treatment solutions for structural heart diseases, peripheral vascular diseases, bradycardia, and neurological diseases. The Company also holds the world’s first innovative iron-based bioabsorbable material technology platform. Adhering to the core strategy of innovation and internationalization, the Company maintains a leading market share of its main products in the home country. To date, it has established 7 subsidiaries outside the China mainland. Its business network spans nearly 120 countries and regions worldwide, underscoring its extensive global footprint.

 

Smart HVAC Systems to Revolutionise Building Efficiency, Cybersecurity, and Customer Experience

LONDON, March 29, 2025 /PRNewswire/ — The global HVAC industry is undergoing a transformational shift, driven by the convergence of IoT, cloud computing, artificial intelligence (AI), and sustainability initiatives. These trends are redefining how heating, ventilation, and air conditioning systems are designed, managed, and secured across residential, commercial, and industrial environments.

Frost & Sullivan’s latest analysis of the HVAC sector highlights the growing role of smart and connected HVAC solutions in enhancing operational efficiency, reducing energy consumption, and ensuring long-term sustainability. The widespread adoption of IoT sensors and cloud-based platforms now enables real-time monitoring, predictive analytics, and proactive maintenance – minimising downtime while maximising performance.

At the same time, the rise of AI and machine learning (ML) is unlocking powerful data-driven insights, helping to optimise system operations, extend equipment lifespan, and tailor climate control to occupant needs. These technologies also support smarter retrofitting decisions and improved design planning in both new and existing buildings.

Cybersecurity Emerges as a Core Priority for Smart HVAC

With HVAC systems increasingly integrated into wider building automation and enterprise IT networks, cybersecurity is taking centre stage. Smart HVAC represents a growing target segment for the cybersecurity industry, prompting a push toward robust, end-to-end solutions.

“Securing connected systems requires identifying unauthorized devices, monitoring abnormal behaviour, encrypting sensitive data, and implementing strict access controls,” says Dennis Marcell Victor, Growth Expert at Frost & Sullivan. “Adopting a zero-trust framework with continuous monitoring and network segmentation will be essential to ensure resilience.”

AI and ML will be pivotal in detecting threats in real time, while integrated cybersecurity solutions – including ransomware prevention and device authentication – are expected to become standard in next-generation HVAC deployments.

Energy-Efficient Innovations and Evolving Business Models

Environmental regulations and global sustainability goals are driving HVAC manufacturers to adopt low-GWP refrigerants and design systems optimized for energy efficiency. Meanwhile, the booming demand for precision cooling in data centres – fuelled by cloud computing and edge technologies – is pushing innovation in scalable, high-performance HVAC systems.

In addition, the emergence of HVAC-as-a-Service (HVACaaS) is transforming how customers engage with HVAC providers. Offering flexible, subscription-based models, HVACaaS reduces capital expenditures while delivering guaranteed performance, proactive service, and enhanced customer satisfaction.

Enabling Smarter Buildings Through Interoperability

The adoption of open communication protocols such as BACnet/IP and Modbus is gaining traction, ensuring seamless integration between HVAC systems and broader building management infrastructure. This trend supports vendor-agnostic environments and promotes greater flexibility in system upgrades and expansions.

As the HVAC industry continues to evolve, companies that embrace digital transformation, prioritise cybersecurity, and align with sustainable practices will be best positioned to lead in the era of smart buildings and connected ecosystems.

See what’s next: click here to help transform your HVAC strategy for a smarter tomorrow.

YOUR TRANSFORMATIONAL GROWTH JOURNEY STARTS HERE. Frost & Sullivan’s Growth Pipeline Engine, transformational strategies and best-practice models drive the generation, evaluation, and implementation of powerful growth opportunities. Is your company prepared to survive and thrive through the coming transformation? Join the Journey

Editor’s Note

To arrange an interview or for any questions, please contact:

Kristina Menzefricke
Marketing & Communications
Global Customer Experience, Frost & Sullivan
kristina.menzefricke@frost.com

Baidu’s Apollo Go Enters Strategic Partnership with Dubai RTA to Deploy Robotaxis in Dubai

  • The first 100 Apollo Go autonomous vehicles to be deployed in Dubai by the end of 2025, with no less than 1,000 to be deployed over the next three years
  • This marks a major milestone in Apollo Go’s international expansion, after it was granted the very first autonomous vehicle pilot license in Hong Kong

BEIJING, March 29, 2025 /PRNewswire/ — Baidu Inc. (NASDAQ: BIDU and HKEX: 9888) today announced that its autonomous ride-hailing platform, Apollo Go, has signed a strategic cooperation agreement with the Roads and Transport Authority (RTA) of Dubai to launch autonomous driving testing and services in the city. This marks Apollo Go’s first international fleet deployment outside of mainland China and Hong Kong, and its first entry into the Middle East.

As part of the agreement, Apollo Go will deploy 100 fully autonomous vehicles in urban Dubai by the end of 2025, using its 6th-generation, purpose-built RT6 robotaxi, with plans to scale the fleet to no fewer than 1,000 by 2028.

“We see strong synergy between our mission and Dubai‘s ambitious vision for autonomous transportation,” said Yunpeng Wang, Corporate Vice President of Baidu and President of Baidu’s Intelligent Driving Group. “It is a privilege to partner with the RTA and support its goal of making 25% of the city’s transportation autonomous by 2030. With Apollo Go’s proven success in China and Baidu’s cutting-edge expertise in AI and autonomous driving, we are excited to introduce safe, efficient, and sustainable autonomous mobility solutions to the region.”

Over the past few years, Dubai has emerged as a pioneer in the global autonomous driving space, with the RTA actively promoting the technology’s commercial application. Through this partnership, Apollo Go will share technical, operational, and regulatory expertise gained from years of deployment across major Chinese cities. This includes its large-scale deployment in Wuhan — a city of over 10 million people — which served as a key technical and operational proving ground. All tests and services will be conducted in line with Dubai‘s local laws and adapted for regional needs to ensure seamless localized operation.

The collaboration aims to integrate autonomous ride-hailing into Dubai‘s broader transportation ecosystem, offering enhanced mobility services for residents and contributing to the city’s intelligent infrastructure goals.

Apollo Go’s deployment will begin directly in the heart of Dubai, where a complex urban traffic environment will test the maturity and stability of its autonomous driving system. Having achieved over 150 million kilometers of safe driving and provided more than 10 million rides to the public, Apollo Go stands as one of the world’s largest autonomous ride-hailing platforms.

The RT6 model, purposefully built for driverless mobility, features enhanced reliability, exceptional comfort and an intuitive design, providing a refined and optimized autonomous vehicle experience for users. With the RTA partnership, Apollo Go plans to bring this same level of service to Dubai — and beyond — in partnership with local authorities.

The announcement of the collaboration came one month after Robin Li, co-founder and CEO of Baidu, attended the World Governments Summit in Dubai in February 2025 and met with local leaders. The agreement with the RTA underscores the UAE government’s strong trust and support for Apollo Go’s technology and vision.

This partnership is the latest milestone in Apollo Go’s global expansion, after it was granted the first autonomous driving test licenses in Hong Kong in November 2024, Apollo Go’s first entry into a right-hand-drive market. Having begun testing in Hong Kong, Apollo Go has now chosen Dubai as the first official international market outside China to deploy a fleet as the company rapidly expands its global footprint.

As Apollo Go continues to scale internationally, the company remains committed to delivering safe, green, and intelligent mobility services in collaboration with global partners to drive the future of urban transportation — making cities smarter, more connected, and ready for the autonomous era.

About Baidu

Founded in 2000, Baidu’s mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on the NASDAQ under “BIDU” and HKEX under “9888.” One Baidu ADS represents eight Class A ordinary shares.